Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry

Oksana A. Shlobin, Vasilis Kouranos, Scott D. Barnett, Esam H. Alhamad, Daniel A. Culver, Joseph Barney, Francis C. Cordova, Eva M. Carmona, Mary Beth Scholand, Marlies Wijsenbeek, Sivagini Ganesh, Elyse E. Lower, Peter J. Engel, John Wort, Laura Price, Athol U. Wells, Steven D. Nathan, Robert P. Baughman
European Respiratory Journal 2020 55: 1901747; DOI: 10.1183/13993003.01747-2019
Oksana A. Shlobin
1INOVA Fairfax Hospital, Falls Church, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: oksana.shlobin@inova.org
Vasilis Kouranos
2Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott D. Barnett
1INOVA Fairfax Hospital, Falls Church, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esam H. Alhamad
3King Saud University, Riyadh, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel A. Culver
4Cleveland Clinic, Cleveland, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Barney
5University of Alabama, Birmingham, AL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francis C. Cordova
6Temple University, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva M. Carmona
7Mayo Clinic, Rochester, MN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Beth Scholand
8University of Utah, Salt Lake City, UT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mary Beth Scholand
Marlies Wijsenbeek
9Erasmus University Medical Centre, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sivagini Ganesh
10University of Southern California, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elyse E. Lower
11University of Cincinnati Medical Center, Cincinnati, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Engel
12The Christ Hospital, Cincinnati, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Wort
2Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Price
2Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athol U. Wells
2Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven D. Nathan
1INOVA Fairfax Hospital, Falls Church, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert P. Baughman
11University of Cincinnati Medical Center, Cincinnati, OH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction Sarcoidosis-associated pulmonary hypertension (SAPH) is associated with reduced survival in single-centre studies. The international Registry for SAPH (ReSAPH) with long-term follow-up was established to enrich our knowledge of this complication of sarcoidosis. This analysis aims to elucidate factors associated with reduced transplant-free survival in SAPH patients.

Methods ReSAPH contains prospectively collected outcomes of SAPH patients since the time of registry enrolment. Information analysed includes right heart catheterisation data, pulmonary function testing, chest radiography, Scadding stage and 6-min walk distance (6MWD), among others. Cox regression models were used to identify independent predictors of transplant-free survival.

Results Data from 215 patients followed for a mean±sd 2.5±1.9 years were available for analysis. In the 159 precapillary patients, the Kaplan–Meier-adjusted 1-, 3- and 5-year transplant-free survival was 89.2%, 71.7% and 62.0%, respectively. Kaplan–Meier-adjusted 1-, 3- and 5-year transplant-free survival in the incident group was 83.5%, 70.3% and 58.3%, respectively, and in the prevalent group was 94.7%, 72.2% and 66.3%, respectively. Patients with reduced diffusing capacity of the lung for carbon monoxide (DLCO) (<35% predicted) and 6MWD <300 m in the precapillary cohort had significantly worse transplant-free survival. Reduced 6MWD and preserved forced expiratory volume (FEV1)/forced vital capacity (FVC) ratio were identified as independent risk factors for reduced transplant-free survival in the precapillary cohort.

Conclusion Reduced DLCO (<35% pred) and 6MWD (<300 m) at the time of registry enrolment were associated with reduced transplant-free survival in the overall precapillary cohort. Preserved FEV1/FVC ratio was identified as an independent risk factor for worsened outcomes.

Abstract

Decreased 6-min walk distance and reduced diffusion capacity are associated with decreased survival in patients with sarcoidosis-associated pulmonary hypertension http://bit.ly/2UQfWJh

Introduction

Sarcoidosis is a multisystem disease prevalent throughout the world [1, 2]. Lung involvement in sarcoidosis is seemingly invariable, with up to 95% of patients manifesting some form of pulmonary disease during the course of their lifetime. Sarcoidosis-associated pulmonary hypertension (SAPH) is a complication associated with significant morbidity and increased mortality [3].

From 2010 to 2013, the reported incidence of sarcoidosis in the Unites States ranged between 7.6 and 8.4 per 100000 insured patients with an expected prevalence of ∼60.0 per 100 000 [4]. The reported prevalence of SAPH is between 6% and 20% at rest and up to 43% with exercise [3, 5–9], with rates of 75% in those listed for lung transplantation [4].

SAPH is categorised as group 5 pulmonary hypertension [10, 11]. Although SAPH occurs more frequently in patients with fibrotic disease, it has been described in those without parenchymal involvement [12]. In addition to fibrotic distortion of the pulmonary vasculature from parenchymal fibrosis, other factors may be related to the granulomatous changes of the pulmonary vasculature found on both arterial and venous sides. Additionally, extrapulmonary factors such as extrinsic mechanical compression of the large pulmonary arteries by hilar lymphadenopathy or fibrosing mediastinitis may play a role, as well as their associated comorbidities, including obstructive sleep apnoea, liver disease and heart failure [13].

Since SAPH is relatively rare, the most practical way to further explore this previously underappreciated entity is through the inception of prospective registries. Therefore, an observational international Registry for Sarcoidosis Associated Pulmonary Hypertension (ReSAPH) was established to prospectively collect data on patients with both incident and prevalent SAPH. We have previously reported the baseline characteristics of the ReSAPH population [14] and now provide an analysis of outcomes for the precapillary subset of patients.

Materials and methods

Patients with a diagnosis of sarcoidosis based on the American Thoracic Society/European Respiratory Society (ERS)/World Association of Sarcoidosis and Other Granulomatous Diseases criteria [15], data from at least one follow-up visit and a haemodynamic diagnosis of pulmonary hypertension were enrolled in an 11-centre observational registry [14], initiated in October 2011. All patients were required to have at least one right heart catheterisation (RHC) demonstrating a mean pulmonary artery pressure (mPAP) ≥25 mmHg, in accordance with the 2015 European Society of Cardiology/ERS guidelines definition [10]. Incident cases were defined as the diagnosis of pulmonary hypertension within 1 year of entry into the registry, whereas prevalent cases were historically diagnosed more than a year prior. All information was recorded in a secure web-based electronic database (REDCap) [16]. Local institutional review board approval was obtained prior to entering any patient into the database. The authors used the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist in preparing this report [17].

For each incident patient, the first RHC identifying pulmonary hypertension was used for diagnosis and to calculate transplant-free survival. For prevalent patients, survival time was calculated as time from registry entry. For example, a prevalent patient diagnosed 1 year prior to registry entry and followed for 5 years from diagnosis had survival time left-truncated at year 1 and right-censored at year 4 (48 months). RHC values recorded included the mean right atrial pressure (RAP), mPAP and systolic (sPAP) and diastolic (dPAP) pulmonary artery pressures, as well as the pulmonary capillary wedge pressure (PCWP) and thermodilution cardiac output. Pre-capillary SAPH was defined as an mPAP ≥25 mmHg with a PCWP of ≤15 mmHg [10]. Calculated pulmonary vascular resistance (cPVR) was calculated as mPAP − PCWP/cardiac output.

Demographics collected included age, sex, race and duration of sarcoidosis. When available, the most recent chest radiograph at the time of entry into the study was reviewed and staged [18] by the enrolling investigator. Scadding staging was not centrally adjudicated. Physiological studies recorded included forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVC ratio, single-breath diffusing capacity of the lung for carbon monoxide (DLCO) and 6-min walk distance (6MWD) [15, 19, 20]. Investigators were asked to record historical and current use of pulmonary hypertension therapy, but no direction was given regarding choice of treatment. Duration of therapy was not captured. Demographics of patients on and off pulmonary arterial hypertension (PAH) therapy were compared. Predefined cut-points of 6MWD, DLCO, mPAP and cPVR were examined for their association with transplant-free survival [21–23].

The participating clinical centres were University of Cincinnati Medical Center (Cincinnati, OH, USA), Cleveland Clinic (Cleveland, OH), Inova Fairfax Hospital (Falls Church, VA, USA), University of Alabama (Birmingham, AL, USA), Temple University (Philadelphia, PA, USA), University of Southern California (Los Angeles, CA, USA), University of Utah (Salt Lake City, UT, USA), Mayo Clinic (Rochester, MN, USA), Erasmus University Medical Centre (Rotterdam, the Netherlands), The Christ Hospital (Cincinnati, OH), the Royal Brompton Hospital (London, UK) and King Saud University (Riyadh, Saudi Arabia).

Statistical analysis

Statistical analysis was performed using STATA 11.0 (Stata Corp., College Station, TX, USA), and SAS (version 9.4; Cary, NC, USA). Data are presented as mean±sd or n (%), where appropriate. Between-group differences were compared using t-test, Chi-squared test, Fisher's exact test or the Mann–Whitney–Wilcoxon rank-sum test, as appropriate. Time to survival was calculated from the date of the first identifying RHC for incident patients and the date of SAPH diagnosis for prevalent patients. The Kaplan–Meier method was used to estimate the cumulative probability of outcomes, and between-group differences were compared using the log-rank test. Univariate Cox proportional hazard models were used to assess association between baseline covariates and all-cause mortality (presented as hazard ratio (HR) and 95% confidence intervals). Univariate parameters were considered for inclusion in multivariate models with p<0.10. For final multivariate models, p<0.05 was considered statistically significant. For expected collinear terms (i.e. sPAP, dPAP, mPAP), those with the lowest p-value were deemed most statistically significant and included in multivariate models. Kaplan–Meier analysis was used to assess differences in cumulative survival. Transplanted patients were considered right-censored at the time of transplant. All statistical tests involving group comparisons were two-tailed, with p-values <0.05 considered statistically significant.

Results

Description of baseline data for the precapillary cohort

There were 215 patients enrolled over a 6-year period (last date of entry September 12, 2017) (figure 1). The majority of patients (159 (73.9%) out of 215) had precapillary pulmonary hypertension, with 60% of patients enrolled from the USA, 24% from Western Europe and 16% from Saudi Arabia. A list of participating centres is included in the materials and methods section. The mean age of the overall precapillary cohort (referred to as the “precapillary cohort” from here on) was 56.9±10.6 years with 72.3% female, 56% African American and 31.4% Caucasian and a mean duration between the time of initial sarcoidosis diagnosis and SAPH of 12.6±11.8 years (table 1). 125 (78.6%) patients had documentation of radiographic Scadding staging (table 2).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Registry for Sarcoidosis-Associated Pulmonary Hypertension (ReSAPH) flowchart. mPAP: mean pulmonary artery pressure; PCWP: pulmonary capillary wedge pressure.

View this table:
  • View inline
  • View popup
TABLE 1

Precapillary cohort demographics

View this table:
  • View inline
  • View popup
TABLE 2

Pulmonary function tests, 6-min walk distance (6MWD) and radiography staging in the precapillary cohort

A comprehensive haemodynamic profile was available in 148 (93.1%) of the patients (no cardiac output documented in 11 patients) (table 1). The mean mPAP of the cohort was 36.9±9.2 mmHg (figure 2a), mean PCWP 9.3±3.2 mmHg and mean cardiac output 5.4±1.7 L·min−1. The mean cPVR was 5.9±3.4 Wood units (WU) (figure 2b), while the mean TPR was 7.8±3.9 WU.

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Distribution of a) mean pulmonary artery pressure (mPAP) and b) calculated pulmonary vascular resistance (cPVR) in the precapillary cohort.

The mean FVC of the group was 62.4±19.7% predicted with a mean DLCO 40.0±15.9% pred. Airflow obstruction (FEV1/FVC <70%) was identified in 58 (36.5%) out of 159 patients (table 1). Patients were limited functionally, with a mean 6MWD of 302.6±119.3 m (table 2), with no correlation between the mPAP and 6MWD (r=−0.11, p<0.187) (figure 3). 122 (76.7%) of patients were on sarcoidosis-specific treatment at the time of study entry, whereas PAH-specific treatment was reported in 115 (72.3%) of patients (table 3).

FIGURE 3
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3

Mean pulmonary artery pressure (mPAP) versus 6-min walk distance (6MWD) in the precapillary cohort.

View this table:
  • View inline
  • View popup
TABLE 3

Pulmonary artery hypertension-specific agent use# in the precapillary cohort

Comparison of incident versus prevalent precapillary subgroups at baseline

Demographics were similar between the incident (n=81, 50.9%) and prevalent groups (n=78, 49.1%), except for race, with a higher percentage of African Americans in the latter group (65.4% versus 46.9%) (table 1). In the prevalent group, the average time from SAPH diagnosis to entry into the registry was 60.4±46.5 months and the average time from most recent RHC and enrolment into the registry was 15.2±9.7 months. In the incident group, the average time from SAPH diagnosis to registry enrolment was 3.7±6.1 months. Pulmonary function tests demonstrated similar restriction; however, the incident cohort demonstrated less obstruction by FEV1/FVC ratio (75.2±16.1 versus 66.6±16.2, p=0.001), and a higher mean DLCO (12.1±13.3 mmol·min-1·mmHg-1 versus 6.8±4.6 mmol·min-1·mmHg-1, p=0.003). The severity of pulmonary hypertension was similar between groups, although the sPAP was slightly higher numerically in the prevalent cohort (56.2±14.1 mmHg versus 60.2±15.7 mmHg, p=0.0939). The prevalent group was much more likely to be treated with PAH-specific therapy and receive a lower dose of prednisone.

Transplant-free survival analysis of the precapillary cohort

41 (25.8%) patients died and nine (5.7%) were transplanted. Overall, the Kaplan–Meier-adjusted 1-, 3- and 5-year transplant-free survival was 89.2%, 71.7% and 62.0%, respectively. In the incident subgroup, the Kaplan–Meier-adjusted 1-, 3- and 5-year transplant-free survival was 83.5%, 70.3% and 58.3%. In the prevalent subgroup, the Kaplan–Meier-adjusted 1-, 3- and 5-year transplant-free survival was 94.7%, 72.2% and 66.3%, respectively. There was no difference in transplant-free survival between the two subgroups (p<0.202) (figure 4).

FIGURE 4
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4

Kaplan–Meier transplant-free survival curves for incident and prevalent subgroups.

In the precapillary cohort, transplant-free survival was not associated with any demographic characteristics, including age, sex or race. Nor was the presence of parenchymal nor fibrocystic disease on chest radiography associated with outcomes. Severe pulmonary hypertension (defined as mPAP ≥35 mmHg) and median cPVR ≥4.4 WU were not predictors of worse outcome. However, severe gas transfer impairment (DLCO <35% pred) and 6MWD <300 m were strong predictors of decreased transplant-free survival (p=0.015 and p<0.001, respectively) (figure 5). In the prevalent cohort, 6MWD <300 m was found to be a predictor of decreased transplant-free survival (p<0.009) (figure 6a). In the incident cohort, both severe gas transfer impairment and 6MWD <300 m were strong predictors of decreased transplant-free survival (p<0.037 and p<0.002, respectively) (figure 6b). When the most recent definition of pulmonary hypertension [11] was applied to the cohort, exclusion of 20 patients with cPVR <3 WU did not change the above associations (graphs not provided). The use of PAH-specific medication at time of enrolment in the study was not associated with improvement in transplant-free survival; however, patients receiving PAH-specific agents appeared to be have more severe SAPH, with lower DLCO percentages and higher RAP, sPAP, mPAP and cPVR (table 4).

FIGURE 5
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5

Kaplan–Meier transplant-free survival curves for relationship with a) mean pulmonary artery pressure (mPAP) ≥35 mmHg, b) calculated pulmonary vascular resistance (cPVR) ≥4.4 Wood units (WU), c) diffusing capacity of the lung for carbon monoxide (DLCO) threshold of 35% predicted and d) 6-min walk distance (6MWD) threshold of 300 m in the precapillary cohort.

FIGURE 6
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 6

Kaplan–Meier transplant-free survival curves for relationship with i) mean pulmonary artery pressure (mPAP) ≥35 mmHg, ii) calculated pulmonary vascular resistance (cPVR) ≥4.4 Wood units (WU), iii) diffusing capacity of the lung for carbon monoxide (DLCO) 35% predicted and iv) 6-min walk distance (6MWD) threshold of 300 m in a) the prevalent subgroup of the precapillary cohort and b) the incident subgroup of the precapillary cohort.

View this table:
  • View inline
  • View popup
TABLE 4

Comparison of demographics for the precapillary cohort on and off pulmonary artery hypertension (PAH)-specific therapy

Univariate predictors of transplant-free survival in the precapillary cohort

Transplant-free survival was strongly associated with a higher 6MWD (HR 0.95, 95% CI 0.92–0.97; p=0.001), age (HR 1.05, 95% CI 1.05–1.08; p=0.009) and DLCO (HR 0.97, 95% CI 0.94–0.99; p=0.012) (table 5). The only haemodynamic parameter that trended towards statistical significance with transplant-free survival by univariate analysis was sPAP (HR 1.02, 95% CI 1.00–1.04; p=0.051) and a lower FEV1/FVC ratio (HR 1.02, 95% CI 1.00–1.05; p=0.061). Data for incident and prevalent groups are presented in table 5.

View this table:
  • View inline
  • View popup
TABLE 5

Univariate hazard ratios (95% CI) for survival in the precapillary cohort with incident and prevalent subgroups

Multivariate predictors of transplant-free survival in the precapillary cohort

A final multivariate Cox proportional hazards model was created with the independent predictors of outcomes from each domain described herein. Statistically significant parameters with univariate hazard ratios whose p-values were <0.10 were considered for inclusion in the model. For expected collinear terms, such as haemodynamic parameters, variables with the lowest p-value were included in the final model. In the final multivariate model, the FEV1/FVC (HR 1.05, 95% CI 1.06–1.10; p=0.019) and 6MWD (HR 0.94, 95% CI 0.89–0.99; p=0.003) remained independent predictors of outcomes (table 6).

View this table:
  • View inline
  • View popup
TABLE 6

Multivariate hazard ratios (95% CI) for survival for the precapillary cohort with incident and prevalent subgroups

Subgroup analyses

Univariate and multivariate analyses of prevalent/incident subgroups of the overall cohort are shown in tables 5 and 6. In univariate analysis, the DLCO, 6MWD and sPAP in the incident group and 6MWD in the prevalent group (table 5) were statistically significant predictors of transplant-free survival. None of the variables reached statistical significance as predictors of outcomes in either subgroup (table 5) in the multivariate analysis, although in the prevalent cohort, 6MWD was nearly statistically significant (p<0.055).

Discussion

The prevalence and impact of SAPH have only been recently appreciated. Due to the relatively low incidence of SAPH, prior reports have mostly emanated from single-centre retrospective studies [3, 5, 6, 9, 11, 21–30]. To address this issue, we established a multicentre international observational registry to capture the demographics, treatment and outcomes of SAPH across a wide geographic and ethnically diverse population. Demographic characteristics of the first 178 SAPH patients have been reported previously [14]. The present article builds further on that publication and is the largest report to date describing outcomes of patients with SAPH.

Multiple studies have demonstrated that development of pulmonary hypertension is associated with higher mortality in patients with sarcoidosis [1, 3, 5, 11, 25]. In this report, the outcomes of the overall cohort were similar to those previously described [22, 31–33], with a 3-year transplant-free survival of ∼71%. There was no association between mortality and any demographic parameters. Earlier studies have suggested that the presence of pulmonary hypertension was associated with a higher prevalence of stage 4 parenchymal disease [30]. In this registry, Scadding staging was assessed on chest radiographs without central adjudication. With subsequent inherent limitations, of the 79% of SAPH patients with imaging available for Scadding staging, 65.6% had stage 4 disease. Only 2% of patients had stage 1 disease, suggesting that the lack of lung opacities on imaging is a fairly sensitive test for the absence of SAPH.

Although a number of factors was associated with survival in univariate analysis, only the FEV1/FVC ratio and 6MWD withstood the scrutiny of a multivariate analysis to emerge as independently associated with outcomes in the analysed cohort. The demonstrated association of a lower FEV1/FVC with improved outcomes is the first such description. A previous study [30] demonstrated no correlation between obstructive spirometric physiology and SAPH. We speculate that SAPH patients with evidence of obstruction may represent a subset with predominantly airway involvement with possibly less likelihood for contiguous vascular disease, thus portending a better outcome. An alternative explanation may be the reduced lung compliance among patients with higher FEV1/FVC ratios.

There are no published guidelines for treating SAPH. The limited supportive evidence for treating SAPH emanates mostly from single-centre and/or retrospective studies [27, 33–39]. As previously noted in this cohort, US-based centres are less likely to use PAH therapies than non-US centres [14]. The majority of patients (∼72%) were on therapy, similar to a recent French registry where nearly all subjects were treated with off-label medications [6]. The use of PAH-specific therapies at the time of enrolment into the study did not appear to be associated with improved transplant-free survival in this study. However, the length of treatment was not recorded, which may have impacted the results. In addition, treated patients appeared to have more severe SAPH at baseline, possibly implying that the outcomes would be worse without treatment. It is plausible that providers may feel more justified to treat more severe SAPH patients with off-label PAH therapies, thus reflecting an apparent “standard of care” that has evolved based on expert opinion with only one placebo-controlled trial [39].

In the previously published French registry, which enrolled patients with severely affected haemodynamics, 3- and 5-year survival were 74% and 55%, respectively [8]. These findings are quite similar to ours, despite our population representing a more diverse cohort, which includes both incident and prevalent subgroups. As expected, patients in the prevalent cohort had longer transplant-free survival. The explanation for this is probably two-fold: survival bias in the prevalent cohort due to enrichment with less severe cases and lead-time bias as the prevalent subgroup was further along the disease course. The goal of the registry was to capture as many patients with this rare complication of sarcoidosis as possible; therefore, the authors felt the study design was justified.

In PAH, it is typically the variables that reflect right ventricular failure, such as the cardiac index and right atrial pressures, that correlate most closely with outcomes [39]. The ReSAPH cohort had relatively preserved haemodynamics that reflect well-preserved right ventricular function, with only 19% of our patients having right atrial pressures >10 mmHg, while only 28% had cardiac indices <2.5 L·min−1·m−2. In the present analysis, severity of pulmonary hypertension, as measured by mPAP and PVR, was not demonstrated to be associated with worse outcomes. As the registry recruits more patients, we plan to re-analyse the data. A possible explanation for this apparent lack of association might be severity bias; specifically, only including patients with mPAP ≥25 mmHg in the registry and not allowing a wider spectrum of mPAP values might have muted any possible associations. Moreover, the fact that two-thirds of the patients were on PAH therapies might have further impacted any associations with outcomes. Interestingly, the French database, where even more patients were treated with PAH therapies, also failed to demonstrate an association between any haemodynamic parameter and survival [8].

Most patients in our cohort were treated with prednisone therapy. The treatment with anti-inflammatory medications has not demonstrated consistent benefit in SAPH, although response rates of 20–30% have been reported in small series [33]. Moreover, none of these studies included patients with stage IV fibrocystic disease, which represents the majority of the ReSAPH patient population. The use of steroid therapy was not associated with better outcomes in the ReSAPH nor French [8] registries.

In sarcoidosis, the presence of pulmonary hypertension is associated with decreased 6MWD [5, 9, 30]. In this analysis, the 6MWD was by far the strongest predictor of mortality, in the main cohort and both prevalent and incident subgroups. This association provides support for the use of the 6MWD as a functional and potentially modifiable surrogate end-point for future clinical trials in SAPH. Although some interventional studies of PAH therapies in patients with SAPH have failed to show a response in 6MWD to therapy [35, 38], there are other studies that attest to its utility as a responsive surrogate for therapeutic efficacy [27, 37].

In summary, this study is the largest registry to date of both incident and prevalent patients with precapillary SAPH. Although this analysis has inherent limitations of registry data including some missing data, it clearly demonstrates that functional impairment (as demonstrated by the 6MWD) and reduced diffusing capacity are associated with decreased survival in SAPH patients. The interesting association of an obstructive phenotype and improved outcomes has not been reported previously and needs to be examined further. Our description of outcomes in a diverse population of SAPH patients highlights a number of issues pertaining to this underappreciated entity that will hopefully form a foundation for future studies. Factors independently associated with outcomes included physiological (FEV1/FVC ratio and diffusing capacity) and functional (6MWD) parameters. These same factors might help to inform future SAPH clinical trials with regards to enrichment (DLCO and FEV1/FVC ratio) and outcomes (6MWD).

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-01747-2019.Shareable

Footnotes

  • This article has an editorial commentary: https://doi.org/10.1183/13993003.00700-2020

  • This study is registered at www.clinicaltrials.gov with identifier number NCT01467791.

  • Author contributions: S.D. Barnett, V. Kouranos, O.A. Shlobin and A.U. Wells performed all data analyses, and O.A. Shlobin was responsible for drafting the manuscript. O.A. Shlobin, V. Kouranos, R.P. Baughman, A.U. Wells and S.D. Nathan all provided significant input into the writing of the manuscript. All authors contributed to patient entry and supervising data entry at each of their sites. All authors reviewed the final manuscript.

  • Conflict of interest: O.A. Shlobin reports personal fees for consultancy from United Therapeutics, Bayer and Johnson & Johnson, outside the submitted work.

  • Conflict of interest: V. Kouranos has nothing to disclose.

  • Conflict of interest: S.D. Barnett has nothing to disclose.

  • Conflict of interest: E.H. Alhamad has nothing to disclose.

  • Conflict of interest: D.A. Culver reports institutional funding for the registry from Gilead, during the conduct of the study; personal fees for advisory board work from Johnson and Johnson, outside the submitted work.

  • Conflict of interest: J. Barney has nothing to disclose.

  • Conflict of interest: F.C. Cordova has nothing to disclose.

  • Conflict of interest: E.M. Carmona reports financial support for the clinical trial from Gilead, during the conduct of the study; personal fees for consultancy and developing education materials from CHEST, personal fees for editorial work from Elsevier, outside the submitted work.

  • Conflict of interest: M.B. Scholand has performed advisory board work and been investigator in clinical trials for Boehringer Ingelheim and Genentech, and been investigator in clinical trials for Fibrogen and Global Blood Therapeutics, outside the submitted work; and has a patent Apparatus, Compositions and Methods for Assessment of Chronic Obstructive Pulmonary Disease Progression among Rapid and Slow Decline Conditions issued.

  • Conflict of interest: M. Wijsenbeek has nothing to disclose.

  • Conflict of interest: S. Ganesh has nothing to disclose.

  • Conflict of interest: E.E. Lower reports grants from Gilead, Bayer and Genentech, during the conduct of the study.

  • Conflict of interest: P.J. Engel has nothing to disclose.

  • Conflict of interest: J. Wort reports grants and personal fees from Actelion Pharmaceuticals and Bayer Pharmaceuticals, personal fees from MSD, outside the submitted work.

  • Conflict of interest: L. Price reports personal fees and education support from Actelion and Johnson & Johnson, during the conduct of the study.

  • Conflict of interest: A.U. Wells reports personal fees from Boehringer Ingelheim, Roche, Intermune and Bayer, outside the submitted work.

  • Conflict of interest: S.D. Nathan reports personal fees for consultancy from United Therapeutics, Bayer Pharmaceuticals, Bellerophon and Actelion, during the conduct of the study.

  • Conflict of interest: R.P. Baughman reports grants from Gilead, Bayer, Genentech, Foundation for Sarcoidosis Research and National Institutes of Health, grants and personal fees for consultancy from Actelion, grants and personal fees for consultancy and lectures from Mallinckrodt, during the conduct of the study.

  • Support statement: Gilead Pharmaceuticals provided an unrestricted educational grant to support the registry. The research database at the University of Cincinnati is funded by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) programme, grant 1UL1TR001425-01. The CTSA programme is led by the NIH's National Center for Advancing Translational Sciences (NCATS).

  • Received February 13, 2019.
  • Accepted February 11, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Baughman RP,
    2. Teirstein AS,
    3. Judson MA, et al.
    Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885–1889. doi:10.1164/ajrccm.164.10.2104046
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Rybicki BA,
    2. Major M,
    3. Popovich J Jr., et al.
    Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145: 234–241. doi:10.1093/oxfordjournals.aje.a009096
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Baughman RP,
    2. Engel PJ,
    3. Taylor L, et al.
    Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138: 1078–1085. doi:10.1378/chest.09-2002
    OpenUrlCrossRefPubMed
  4. ↵
    1. Baughman RP,
    2. Field S,
    3. Costabel U, et al.
    Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc 2016; 13: 1244–1252. doi:10.1513/AnnalsATS.201511-760OC
    OpenUrlCrossRefPubMed
  5. ↵
    1. Shorr AF,
    2. Helman DL,
    3. Davies DB, et al.
    Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25: 783–788. doi:10.1183/09031936.05.00083404
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Huitema MP,
    2. Bakker ALM,
    3. Mager JJ, et al.
    Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study. Eur Respir J 2019; 54: 1900897. doi:10.1183/13993003.00897-2019
    OpenUrlAbstract/FREE Full Text
    1. Shlobin OA,
    2. Nathan SD
    . Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J 2012; 39: 1520–1533. doi:10.1183/09031936.00175511
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Boucly A,
    2. Cottin V,
    3. Nunes H, et al.
    Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50: 1700465. doi:10.1183/13993003.00465-2017
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Handa T,
    2. Nagai S,
    3. Miki S, et al.
    Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129: 1246–1252. doi:10.1378/chest.129.5.1246
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Simonneau G,
    2. Robbins IM,
    3. Beghetti M, et al.
    Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43–S54. doi:10.1016/j.jacc.2009.04.012
    OpenUrlFREE Full Text
  10. ↵
    1. Frost A,
    2. Badesch D,
    3. Gibbs JSR, et al.
    Diagnosis of pulmonary hypertension. Eur Respir J 2019; 53: 1801904.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Nunes H,
    2. Humbert M,
    3. Capron F, et al.
    Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61: 68–74. doi:10.1136/thx.2005.042838
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Shlobin OA,
    2. Baughman RP
    . Sarcoidosis-associated pulmonary hypertension. Semin Respir Crit Care Med 2017; 38: 450–462. doi:10.1055/s-0037-1603767
    OpenUrl
  13. ↵
    1. Baughman RP,
    2. Shlobin OA,
    3. Wells AU, et al.
    Clinical features of sarcoidosis associated pulmonary hypertension: results of a multi-national registry. Respir Med 2018; 139: 72–78. 10.1016/j.rmed.2018.04.015.
    OpenUrl
  14. ↵
    1. Judson MA,
    2. Costabel U,
    3. Drent M, et al.
    The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 19–27.
    OpenUrlPubMed
  15. ↵
    1. Obeid JS,
    2. McGraw CA,
    3. Minor BL, et al.
    Procurement of shared data instruments for Research Electronic Data Capture (REDCap). J Biomed Inform 2013; 46: 259–265. doi:10.1016/j.jbi.2012.10.006
    OpenUrlCrossRefPubMed
  16. ↵
    1. von Elm E,
    2. Altman DG,
    3. Egger M, et al.
    The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344–349. doi:10.1016/j.jclinepi.2007.11.008
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Scadding JG
    . Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J 1961; 2: 1165–1172. doi:10.1136/bmj.2.5261.1165
    OpenUrlFREE Full Text
  18. ↵
    1. Hunninghake GW,
    2. Costabel U,
    3. Ando M, et al.
    ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149–173.
    OpenUrlPubMedWeb of Science
  19. ↵
    1. Borg G
    . Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377–381.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Shorr AF,
    2. Davies DB,
    3. Nathan SD
    . Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124: 922–928. doi:10.1016/S0012-3692(15)37649-2
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Arcasoy SM,
    2. Christie JD,
    3. Pochettino A, et al.
    Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001; 120: 873–880. doi:10.1378/chest.120.3.873
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Bourbonnais JM,
    2. Samavati L
    . Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32: 296–302. doi:10.1183/09031936.00175907
    OpenUrlAbstract/FREE Full Text
    1. Nardi A,
    2. Brillet P-Y,
    3. Letounmelin P, et al.
    Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011; 38: 1368–1373. doi:10.1183/09031936.00187410
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Alhamad EH,
    2. Idrees MM,
    3. Alanezi MO, et al.
    Sarcoidosis-associated pulmonary hypertension: clinical features and outcomes in Arab patients. Ann Thorac Med 2010; 5: 86–91. doi:10.4103/1817-1737.62471
    OpenUrlCrossRefPubMed
    1. Głuskowski J,
    2. Hawryłkiewicz I,
    3. Zych D, et al.
    Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration 1984; 46: 26–32. doi:10.1159/000194667
    OpenUrlPubMedWeb of Science
  24. ↵
    1. Keir GJ,
    2. Walsh SL,
    3. Gatzoulis MA, et al.
    Treatment of sarcoidosis-associated pulmonary hypertension: a single centre retrospective experience using targeted therapies. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 82–90.
    OpenUrlPubMed
    1. Kirkil G,
    2. Lower EE,
    3. Baughman RP
    . Predictors of mortality in sarcoidosis. Chest 2018; 153: 105–113. doi:10.1016/j.chest.2017.07.008
    OpenUrlCrossRefPubMed
    1. Patel MB,
    2. Mor-Avi V,
    3. Murtagh G, et al.
    Right heart involvement in patients with sarcoidosis. Echocardiography 2016; 33: 734–741. doi:10.1111/echo.13163
    OpenUrl
  25. ↵
    1. Sulica R,
    2. Teirstein A,
    3. Kakarla S, et al.
    Distinctive clinical, radiographic and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128: 1483–1489. doi:10.1378/chest.128.3.1483
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Baughman RP,
    2. Gerson M,
    3. Bosken CH
    . Right and left ventricular function at rest and with exercise in patients with sarcoidosis. Chest 1984; 85: 301–306. doi:10.1378/chest.85.3.301
    OpenUrlCrossRefPubMedWeb of Science
    1. Hoeper MM,
    2. Behr J,
    3. Held M, et al.
    Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonia. PLoS One 2015; 10: e0141911. doi:10.1371/journal.pone.0141911
    OpenUrl
  27. ↵
    1. Rodman DM,
    2. Lindenfeld J
    . Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest 1990; 97: 500–502. doi:10.1378/chest.97.2.500
    OpenUrlCrossRefPubMedWeb of Science
    1. Fisher KA,
    2. Serlin DM,
    3. Wilson KC, et al.
    Sarocidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130: 1481–1488. doi:10.1378/chest.130.5.1481
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Baughman RP,
    2. Judson MA,
    3. Lower EE, et al.
    Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2008; 26: 110–120.
    OpenUrl
    1. Millman N,
    2. Burton CM,
    3. Iversen M, et al.
    Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant 2008; 75: 329–334. doi:10.1016/j.healun.2007.11.576
    OpenUrl
  29. ↵
    1. Barnett CF,
    2. Bonura EJ,
    3. Nathan SD, et al.
    Treatment of sarcoidosis-associated pulmonary hypertension: a two-center experience. Chest 2009; 135: 1455–1461. doi:10.1378/chest.08-1881
    OpenUrlCrossRefPubMed
  30. ↵
    1. Baughman RP,
    2. Culver DA,
    3. Cordova FC, et al.
    Bosentan for sarcoidosis-associated pulmonary arterial hypertension (BoSAPAH): a double blind, placebo controlled trial. Am J Resp Crit Care Med 2012; 185: A3639. doi:10.1164/ajrccm.185.4.462
    OpenUrl
  31. ↵
    1. Benza RL,
    2. Miller DP,
    3. Barst RJ, et al.
    An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448–456. doi:10.1378/chest.11-1460
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 55 Issue 5 Table of Contents
European Respiratory Journal: 55 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry
Oksana A. Shlobin, Vasilis Kouranos, Scott D. Barnett, Esam H. Alhamad, Daniel A. Culver, Joseph Barney, Francis C. Cordova, Eva M. Carmona, Mary Beth Scholand, Marlies Wijsenbeek, Sivagini Ganesh, Elyse E. Lower, Peter J. Engel, John Wort, Laura Price, Athol U. Wells, Steven D. Nathan, Robert P. Baughman
European Respiratory Journal May 2020, 55 (5) 1901747; DOI: 10.1183/13993003.01747-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry
Oksana A. Shlobin, Vasilis Kouranos, Scott D. Barnett, Esam H. Alhamad, Daniel A. Culver, Joseph Barney, Francis C. Cordova, Eva M. Carmona, Mary Beth Scholand, Marlies Wijsenbeek, Sivagini Ganesh, Elyse E. Lower, Peter J. Engel, John Wort, Laura Price, Athol U. Wells, Steven D. Nathan, Robert P. Baughman
European Respiratory Journal May 2020, 55 (5) 1901747; DOI: 10.1183/13993003.01747-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Ambulatory management of secondary spontaneous pneumothorax
  • Systematic assessment of respiratory health in illness susceptible athletes
  • Identifying early PAH biomarkers in systemic sclerosis
Show more Original Articles

Pulmonary hypertension

  • Echocardiographic probability of PH: a validation study
  • COMPERA 2.0: refined 4-stratum assessment for PAH
  • Selexipag for the treatment of chronic thromboembolic PH
Show more Pulmonary hypertension

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society